10.08.2025, 840 Zeichen

Valneva: Austrian/French Valneva SE, a specialty vaccine company, today announced that the FDA has removed its recommended pause in the use of IXCHIQ^® in individuals 60 years of age and older and has approved updates to the Prescribing Information (PI) for IXCHIQ^®. IXCHIQ^® remains indicated in the United States for the prevention of disease caused by the Chikungunya Virus (CHIKV) in individuals 18 years of age and older who are at high risk of exposure to CHIKV. The FDA decision follows the announcement in July by the European Medicines Agency (EMA)¹ which recommended the lifting of temporary restrictions in elderly people after the conclusion of a thorough review of IXCHIQ^® by its safety committee (PRAC).
Valneva: weekly performance: 21.47%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (07/08/2025)

Christian Drastil: Wiener Börse Plausch

SportWoche ÖTV-Spitzentennis Podcast: ÖTV-Damen dominieren beim WTA-125-Challenger in Kitzbühel, 3x Karrierehoch in Woche 29

Bildnachweis

Aktien auf dem Radar:AT&S, Porr, Agrana, Austriacard Holdings AG, Amag, Polytec Group, Wienerberger, CPI Europe AG, Lenzing, Mayr-Melnhof, FACC, ATX, ATX Prime, ATX TR, ATX NTR, Erste Group, RBI, Frequentis, Marinomed Biotech, Semperit, Wolford, Wolftank-Adisa, Bawag, EuroTeleSites AG, Österreichische Post, Telekom Austria, UBM, Travelers Companies, Fresenius Medical Care, SAP, Deutsche Telekom.

---